Upstream & Downstream Processing

Waters: Strength in biopharma as it takes small molecule hit

Chromatography and measurement company Waters Corporation experienced a volatile Q1 but its biopharma business remains high, backed by significant investments in the space. For the first quarter 2019, Waters Corporation reported sales of $514 million (€458 million), a drop of 3% on the same period last year. Waters CEO Chris O’Connell attributed the unexpected fall in sales to “greater-than-expected macro impacts in China and Europe, as well as a slow release of budgets by key pharmaceutical and industrial customers,” but…

Emerson buys Bio-G, adding modeling and scheduling software

Analytics and modeling tools can help deliver more effective and safer therapies to patients says Emerson, fresh from its acquisition of Bioproduction Group (Bio-G). Terms of the acquisition have not been divulged, but technology and engineering company Emerson extends its life sciences technology portfolio through the addition of Bio-G. “Many of biopharma’s biggest companies use Bio-G’s modeling and scheduling software for de-bottlenecking and optimization, and many of these same companies trust Emerson expertise and software to control their production and…

Danaher’s bioprocess biz bright with China and GE on horizon

With continued double-digit growth in China and the future addition of GE Healthcare’s Biopharma business, Danaher Corporation is poised to strengthen its position in the bioprocess space. Danaher Corporation reported a robust first quarter last week, with 4% year-on-year sales growth across all businesses to $4.9 billion (€4.4 billion). Core revenue from Life Sciences grew 7%, which included contributions from Pall Corporation, a major vendor in the bioprocess space. The firm does not report financials from its individual businesses. “In…

Novasep boosts viral vector offering with access to DNA Flap tech

An agreement between Novasep and Theravectys gives the French CDMO access to the Institut Pasteur’s DNA FLAP technology to produce GMP-grade lentiviral vectors for clinical. The DNA Flap tech allows efficient lentivector-mediated gene transfer either ex vivo or in vitro. It consists of a specific DNA sequence derived from the lentiviral genome, which includes the cPPT and CTS cis-active sequences, required to enable the import of the lentivirus genome into the cell nucleus of non-replicating cells. Theravectys holds a license…

Egg beater: Seqirus goes fully cell-based for seasonal flu vaccine

Seqirus’s vaccine offering for the 2019/20 season will be uniquely cell-base, but the firm says traditional egg-based production still plays a role in fighting influenza. Provided each year by the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS), candidate vaccine viruses (CVVs) are the basis for the development and production of seasonal influenza vaccines. For the 2019/20 season, Seqirus has decided to use a cell-based CVV for all four influenza strains recommended by the WHO for its…

CRISPR consortium launched to improve CHO cell lines

Horizon Discovery has launched an industry consortium aimed at improving the CHO expression platform using modern gene-editing tools such as CRISPR and rAAV. At BPI Europe in Vienna, Austria earlier this month, cell line technologies firm Horizon Discovery announced plans to create an industry group to address inadequacies with the prevalent Chinese hamster ovary (CHO) expression platform by using the gene-editing tools CRISPR (clustered regularly interspaced short palindromic repeats) and rAAV (recombinant adeno-associated virus). “The CHO cell line has hardly…

Cell therapy vendors: News from Miltenyi and Saint-Gobain

Bellicum Pharmaceuticals has inked a supply agreement with Miltenyi Biotec; Hitachi Chemical has teamed with Saint-Gobain to address manufacturing challenges – welcome to Bioprocess Insider’s cell therapy services round-up. In an SEC filing, Houston, Texas-based cellular immunotherapy firm Bellicum Pharmaceuticals revealed it has entered a agreement with Miltenyi Biotec GmbH for the supply of “certain products in connection with the development and manufacture of certain of the Company’s products.” The firm will pay Miltenyi a €2 million ($2.3 million) upfront…

Encroaching titer, hidden danger: Upstream intensification and the downstream mess

Increased titers are driving the need to move to semi and fully-continuous processing in the downstream, UCB’s Stefanos Grammatikos told BPI Europe delegates. In efforts to intensify bioprocesses and accelerate development, industry has traditionally looked to increasing titers. Since the early days of biomanufacturing thirty years ago, titers have risen from less than 0.5 g/L to mid-to-high single-digits. However, some firms claim they are able to drive titers far higher, either through the use of non-mammalian expression systems (in the…

ChromaCon buy and expansions tip YMC further into the biologics space

Japanese separation resins firm YMC has acquired ChromaCon AG, adding a range of continuous chromatography technologies to its ever-increasing large molecules purification portfolio. The deal, financials of which have not been released, saw YMS acquire 100% of ChromaCon shares and intellectual property rights. This includes patents around multi-column processing, the Contichrom benchtop instrument range of products and several license arrangements. “YMC Process Technologies already manufactures and markets GMP production skids embedding ChromaCon technology,” Philipp Anstätt, strategist aligning R&D and market…

Spin-out Cellular Highways looks to next-generation cell-sorting

There is no cell purification technology that allows the selection of cells based on several molecular markers at the same time while processing large batches of cells. That is until the VACS platform, new entity Cellular Highways claims. Tech firm TTP has invested £1.7 million ($2.2 million) in its spin-out firm Cellular Highway in efforts to commercialize the Vortex-Actuated Cell Sorting (VACS) platform. Bioprocess Insider (BI) spoke to Salman Samson Rogers (SSR), CEO of the new entity to find out…